Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia

Infection Control and Hospital Epidemiology

Volumn 30, Issue 10, 2009, Pages 972-976

  Borer, Abraham ^a,e   Saidel Odes, Lisa ^b,e   Riesenberg, Klaris ^b,e   Eskira, Seada ^a,e   Peled, Nejama ^c,e   Nativ, Ronit ^a,e   Schlaeffer, Francisc ^b,e   Sherf, Michael ^d,e  

^a Infection Control

^b Infectious Diseases Institute   (Israel)

^c Clinical Microbiological Laboratory

^d Hospital Administration   (United States)

^e BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COLISTIN; ERTAPENEM; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE; TOBRAMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE; CENTRAL VENOUS CATHETER; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; INTENSIVE CARE; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CARBAPENEMS; CASE-CONTROL STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HOSPITAL MORTALITY; HOSPITALS, TEACHING; HUMANS; ISRAEL; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MATCHED-PAIR ANALYSIS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED;

EID: 70350029293     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/605922     Document Type: Article

References (21)

1. Borer A, Eskira S, Nativ R, et al. Carbapenem-resistant Klebsiella pneumoniae outbreak in southern Israel: from crisis to ongoing control. In: Program and abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America 46th Annual Meeting (Washington, DC). Washington, DC: American Society for Microbiology; and Alexandria, VA: Infectious Diseases Society of America, 2008.
2. Schwaber M, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008; 52:1028-1033.
3. Samra Z, Ofir O, Lishtzinsky Y, Madar-Shapiro L, Bishara J. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int J Antimicrob Agents 2007; 30:525-529.
4. Maltezou HC. Metallo-b-lactamases in gram-negative bacteria: introducing the era of pan-resistance? Int J Antimicrob Agents 2008; 33:405.e1-405.e7.
5. Davey PG, Marwick C. Appropriate vs. inappropriate antimicrobial therapy. Clin Microbiol Infect 2008; 14(Suppl 3):15-21.
6. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee P. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29:1099-1106.
7. Falagas ME, Rafailidis PI, Kofteridis D, et al. Risk factors of carbapenemresistant Klebsiella pneumoniae infections: a matched case-control study. J Antimicrob Chemother 2007; 60:1124-1130.
8. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271:1598-1601.
9. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin- resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996; 23:1234-1239.
10. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36:296-327.
11. Bauer AW, Kirby WMM,Sherris JC, Turk M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1966; 45:493-496.
12. Anderson KF, Lonsway DR, Rasheed JK, et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenase in enterobactereaceae. J Clin Microbiol 2007; 45:2723-2725.
13. CLSI. Performance standards for antimicrobial susceptibility testing: 16th informational supplement. Approved standard; CLSI document. Wayne, PA: CLSI, 2006; M100-S16.
14. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995; 273:117-123.
15. Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003; 37:1172-1177.
16. Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol 2003; 24:690-698.
17. Senol E, DesJardin J, Stark PC, Barefoot L, Snydman DR. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 2002; 34:1653-1656.
18. Redondo CM, Arbo MDJ, Grindlinger J, Snydman DR. Attributable mortality of bacteremia associated with the Bacteroides fragilis group. Clin Infect Dis 1995; 20:1492-1496.
19. Martin MA, Pfaller MA, Wenzel RP. Coagulase-negative staphylococcal bacteremia, mortality and hospital stay. Ann Intern Med 1989; 110:9-16.
20. Cobo J, Morosini MI, Pintado V, et al. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 blactamase- producing Klebsiella pneumoniae epidemic clone. Diagn Microbiol Infect Dis 2008; 60:319-322.
21. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 3136-3146.